SCHEMBL23533271

SCHEMBL23533271

CCCCCCCCCCCCCC(=O)N1CCN(C(=O)O)CC1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.69
GNAI3 P08754 9/20 0.69
GNAI1 P63096 9/20 0.69
TDP1 Q9NUW8 3/20 0.67
MEN1 O00255 2/20 0.67
KMT2A Q03164 2/20 0.67
GNAO1 P09471 8/20 0.60
PPARG P37231 4/20 0.48
PPARD Q03181 4/20 0.48
PPARA Q07869 4/20 0.48
TSHR P16473 3/20 0.48
GPR84 Q9NQS5 3/20 0.48
HDAC11 Q96DB2 3/20 0.48
ALDH1A1 P00352 2/20 0.48
SLC22A6 Q4U2R8 1/20 0.48
SLC22A8 Q8TCC7 1/20 0.48
TLR2 O60603 1/20 0.48
ESR1 P03372 1/20 0.48
FABP4 P15090 1/20 0.48
ALOX15 P16050 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852116 1.00 L3MBTL1 (0.69) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL8972813 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL7060548 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL1044731 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL8972980 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL8972823 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL4450061 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL1045855 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL768398 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1
SCHEMBL9415758 0.92 L3MBTL1 (0.80) L3MBTL1GNAI3GNAI1TDP1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230044749-A1 SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS LUNELLA BIOTECH, INC. (CA) 2023-02-09 US disclosed
US-20230043357-A1 SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS LUNELLA BIOTECH, INC. (CA) 2023-02-09 US disclosed
WO-2021124106-A1 SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS LUNELLA BIOTECH, INC. (CA) 2021-06-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230044749-A1 SELECTIVE CDK 4/6 INHIBITOR CANCER THERAPEUTICS CDK6, CDK4, CDKL4 L3MBTL1 1236/4885GNAI3 1890/4885GNAI1 1998/4885
US-20230043357-A1 SELECTIVE CDK4/6 INHIBITOR CANCER THERAPEUTICS CDK4, CDK6, CDKL4 L3MBTL1 2212/4885GNAI3 2096/4885GNAI1 1917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.